{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:47:08Z","timestamp":1784692028510,"version":"3.55.0"},"reference-count":64,"publisher":"Microbiology Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,1]]},"abstract":"<jats:p>A high intermittent dose regimen (group A: 10\u2005mg\u2005kg<jats:sup>\u22121<\/jats:sup> on day 1, 5\u2005mg\u2005kg<jats:sup>\u22121<\/jats:sup> on days 3 and 6) was compared with standard dosing (group B: 3\u2005mg\u2005kg<jats:sup>\u22121<\/jats:sup>\u2005per day for 14\u2005days) of liposomal amphotericin B (LAB) for empirical treatment of persistent febrile neutropenia. A total cumulative dose of 1275\u2005mg (group A) and 2800\u2005mg (group B) was administered. Infusion-related adverse drug events, mainly rigors\/chills, occurred more frequently with group A (11\/45, 24\u200a% infusions) than with group B (12\/201, 6\u200a% infusions) (<jats:italic>P<\/jats:italic>=0.002), which extended the mean infusion time by 20\u2005min (<jats:italic>P<\/jats:italic>=0.001). Creatinine levels were similar in the two regimens: the A\u200a:\u200aB ratio of the area under the curve for creatinine (AUC<jats:sub>CREATININE<\/jats:sub>) for days 2\u20137 was 1.09 (<jats:italic>P<\/jats:italic>=0.27) and for days 2\u201314 was 1.05 (<jats:italic>P<\/jats:italic>=0.51). Rises in creatinine were mild (clinical toxicity criteria 1) in all patients with elevations. Hypokalaemia tended to be less severe in group A with a lower proportion of hypokalaemic days [57\/143 (39\u200a%) vs 80\/137 (58\u200a%), <jats:italic>P<\/jats:italic>=0.21], a higher AUC<jats:sub>POTASSIUM<\/jats:sub> (A\u200a:\u200aB ratio of 1.06, <jats:italic>P<\/jats:italic>=0.12), a lower proportion of patients with hypokalaemia at the end of study (10 vs 61\u200a%, <jats:italic>P<\/jats:italic>=0.01) and fewer potassium-supplemented days [12\/210 (6\u200a%) vs 41\/210 (19.5\u200a%), <jats:italic>P<\/jats:italic>&lt;0.1]. There were mildly elevated median levels of serum bilirubin, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, which were similar for the two regimens and were usually associated with other co-existing co-morbid conditions. The AUC for these enzymes was also similar in the two groups. No patient had discontinuation of the study drug due to toxicity. Composite success was identical for each regimen (11\/15 patients, 73\u200a%). Three of the fifteen patients in group B and none in group A developed invasive fungal infections (IFIs). <jats:italic>\u03b2<\/jats:italic>-<jats:sc>d<\/jats:sc>-Glucan levels were similar in both groups for patients without an IFI [AUC<jats:sub>GLUCAN<\/jats:sub> of 362 and 683 (<jats:italic>P<\/jats:italic>=0.36) for groups A and B, respectively]. The rate of defervescence was similar for each regimen (<jats:italic>P<\/jats:italic>=0.75). This feasibility study suggests that a short intermittent high-dose course of 10\/5\/5\u2005mg LAB kg<jats:sup>\u22121<\/jats:sup> on days 1, 3 and 6 may be as safe and effective as a standard 14 day course of 3\u2005mg\u2005kg<jats:sup>\u22121<\/jats:sup> per day, with drug-acquisition cost savings and reduced drug exposure. A larger study is indicated for confirmation of this.<\/jats:p>","DOI":"10.1099\/jmm.0.012401-0","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T18:39:15Z","timestamp":1255113555000},"page":"1474-1485","source":"Crossref","is-referenced-by-count":19,"title":["A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever"],"prefix":"10.1099","volume":"58","author":[{"given":"Michael","family":"Ellis","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"},{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"Bernsen","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Ali-Zadeh","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tawam\u2013Johns Hopkins Hospital, Al Ain, UAE"},{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tawam\u2013Johns Hopkins Hospital, Al Ain, UAE"},{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Hedstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine, Al-Ain Hospital, Al Ain, UAE"},{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Poughias","sequence":"additional","affiliation":[{"name":"International Medical Affairs, Gilead Sciences, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bresnik","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awad","family":"Al-Essa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"A. Stevens","sequence":"additional","affiliation":[{"name":"Santa Clara Valley Medical Center, San Jose, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","first-page":"179","article-title":"Effect of tissue penetration on AmBisome efficacy","volume":"4","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"R2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2008.01979.x","article-title":"Amphotericin B lipid preparations: what are the differences?","volume":"14 (Suppl. 4)","author":"Adler-Moore","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jac\/dkh460","article-title":"Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis","volume":"54","author":"Adler-Moore","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R6","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1128\/AAC.42.12.3103","article-title":"Efficacy of low dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients","volume":"42","author":"Camp","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.1998.00934.x","article-title":"A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology","volume":"103","author":"Clark","year":"1998","journal-title":"Br J Haematol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/27.4.535","article-title":"Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients","volume":"27","author":"Collette","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R10","first-page":"10","article-title":"Safety of a weekly administration of 10\u2005mg\/kg of liposomal amphotericin B for antifungal prophylaxis in allogeneic stem-cell transplant and acute leukemia patients","author":"Cordonnier","year":"2005","journal-title":"In American Society of Hematology 47th Annual Meeting"},{"key":"R11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload Trial","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199855040-00008","article-title":"Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis","volume":"55","author":"Coukell","year":"1998","journal-title":"Drugs"},{"key":"R13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1179\/joc.2005.17.1.82","article-title":"Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion","volume":"17","author":"Demartini","year":"2005","journal-title":"J Chemother"},{"key":"R14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49 (Suppl. 1)","author":"Deray","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":"High dose weekly liposomal amphotericin B antifungal prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation","volume":"39","author":"El-Cheikh","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0161-5890(02)00022-6","article-title":"Invasive fungal infections: evolving challenges for diagnosis and therapeutics","volume":"38","author":"Ellis","year":"2002","journal-title":"Mol Immunol"},{"key":"R18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.2004.04903.x","article-title":"Preventing microbial translocation in haematological malignancy","volume":"125","author":"Ellis","year":"2004","journal-title":"Br J Haematol"},{"key":"R19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1469-0691.2008.01982.x","article-title":"New dosing strategies for liposomal amphotericin B in high-risk patients","volume":"14 (Suppl. 4)","author":"Ellis","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/AAC.36.1.172","article-title":"Double blind randomized study of the effect of infusion rates on toxicity of amphotericin B","volume":"36","author":"Ellis","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R21","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1086\/319201","article-title":"Severe hepatic injury associated with lipid formulations of amphotericin B","volume":"32","author":"Ellis","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R22","article-title":"Pharmacokinetics, efficacy of 3mg\/kg\/day vs 10mg\/kg day 1, 5\u2005mg\/kg days 3 and 6 liposomal amphotericin B (Ambisome) in febrile neutropenia","volume-title":"In 8th Congress of the European Association for Clinical Pharmacology and Therapeutics","author":"Ellis","year":"2007"},{"key":"R23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1099\/jmm.0.47479-0","article-title":"Assessment of the clinical utility of serial \u03b2 -d-glucan concentrations in patients with persistent neutropenic fever","volume":"57","author":"Ellis","year":"2008","journal-title":"J Med Microbiol"},{"key":"R24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","year":"1989","journal-title":"Am J Med"},{"key":"R25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"BMJ"},{"key":"R26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2005.06.090","article-title":"Outcome of induction and post-remission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group study","volume":"23","author":"Farag","year":"2005","journal-title":"J Clin Oncol"},{"key":"R27","doi-asserted-by":"crossref","DOI":"10.1002\/0471445428","volume-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"2003"},{"key":"R28A","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/169.2.356","article-title":"Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of brochoalveolar d-mannitol and serum galactomannan as markers of infection","volume":"169","author":"Francis","year":"1994","journal-title":"J Infect Dis"},{"key":"R28","first-page":"19","article-title":"Use of high-dose liposomal amphotericin B: efficacy and tolerance","volume":"77 (Suppl. 4)","author":"Garbino","year":"2006","journal-title":"Acta Biomed"},{"key":"R29","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1128\/AAC.44.9.2327-2332.2000","article-title":"Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis","volume":"44","author":"Garcia","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R31","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2008.06.040","article-title":"Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis","volume":"44","author":"Goldberg","year":"2008","journal-title":"Eur J Cancer"},{"key":"R32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1592\/phco.22.12.961.33607","article-title":"Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients","volume":"22","author":"Gubbins","year":"2002","journal-title":"Pharmacotherapy"},{"key":"R34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin B (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind placebo-controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMe048203","article-title":"Antifungal therapy in patients with fever and neutropenia \u2013 more rational and less empirical?","volume":"351","author":"Klastersky","year":"2004","journal-title":"N Engl J Med"},{"key":"R37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2008.01984.x","article-title":"Liposomal amphotericin B: what is its role in 2008?","volume":"14 (Suppl. 4)","author":"Lanternier","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"R39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/QCO.0b013e328307c7d9","article-title":"Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies","volume":"21","author":"Marr","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"R40","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1473-3099(02)00371-7","article-title":"Antifungal drug resistance to azoles and polyenes","volume":"2","author":"Masi\u00e1 Canuto","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"R41","article-title":"Medical Research Council Acute Lymphoblastic Leukemia Trial XII (UKALL XII), version 4.1, February 2006. Joint Trial with Eastern Cooperative Group (ECOG) \u2013 E2993. Protocol for adults with ALL","year":"2006","journal-title":"Modified for intrathecal therapy and Philadelphia Positive ALL"},{"key":"R42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/28.suppl_B.83","article-title":"Liposomal amphotericin B (AmBisome): safety data from a phase II\/III clinical trial","volume":"28 (Suppl. B)","author":"Meunier","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb04825.x","article-title":"Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients","volume":"86","author":"Mills","year":"1994","journal-title":"Br J Haematol"},{"key":"R45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","article-title":"Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections","volume":"69","author":"Moen","year":"2009","journal-title":"Drugs"},{"key":"R46","volume-title":"Common Toxicity Criteria , version 2.0","year":"1998"},{"key":"R47","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.00315-06","article-title":"Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine aspergillosis model","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u2018gold standard\u2019","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"for the Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore"},{"key":"R50","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized single center trial","volume":"17","author":"Penack","year":"2006","journal-title":"Ann Oncol"},{"key":"R51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"R52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol"},{"key":"R53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/jac\/dkm077","article-title":"Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B","volume":"59","author":"Smith","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R54","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1592\/phco.26.6part2.47S","article-title":"Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques","volume":"26","author":"Sobel","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R55","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/jac\/dkl005","article-title":"Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis","volume":"57","author":"Takemoto","year":"2006a","journal-title":"J Antimicrob Chemother"},{"key":"R56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1348-0421.2006.tb03832.x","article-title":"Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans","volume":"50","author":"Takemoto","year":"2006b","journal-title":"Microbiol Immunol"},{"key":"R57","first-page":"681","article-title":"Biodistribution of 4-[14C]cholesterol\u2013AmBisome following a single intravenous administration to rats","volume":"29","author":"Townsend","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R58","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","article-title":"Amphotericin B distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R59","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persisting fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"R60","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"R62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"R63","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.012401-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T07:20:53Z","timestamp":1601277653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.012401-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,1]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.012401-0","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,1]]}}}